Literature DB >> 18638001

Risk factors for emotional and relationship problems in Peyronie's disease.

James F Smith1, Thomas J Walsh, Simon L Conti, Paul Turek, Tom Lue.   

Abstract

INTRODUCTION: Peyronie's disease (PD) occurs in 3-9% of all men. Little is known regarding the specific psychological or emotional disruptions to sexuality associated with PD. AIM: Our primary aim was to identify risk factors associated with psychosocial difficulties in men with PD.
METHODS: This cross-sectional study enrolled patients from a single clinical practice. Detailed medical histories, physical examinations, and a PD-specific questionnaire were used to define clinical characteristics. Odds ratios (ORs) were used as a measure of association. MAIN OUTCOME MEASURES: Emotional and relationship problems were determined by "yes" or "no" answers to two specific questions.
RESULTS: The mean age of all PD patients (N = 245) was 54.4 years (range 19.4-75.6); 62% were married, and 59% presented within 2 years of disease onset. The overall prevalence of emotional and relationship problems attributable to PD was 81% and 54%, respectively. Among men who had relationship problems, the prevalence of emotional problems was 93%. In men with emotional problems due to PD, relationship issues were observed in 62%. Multivariable analysis revealed that emotional difficulties (OR 6.9, P < 0.001) and ability to have intercourse (OR 0.4, P = 0.004) were independently associated with relationship problems. Relationship problems (OR 8.0, P < 0.001) and loss of penile length (OR 2.7, P = 0.02) were significant independent predictors of emotional problems after adjustment for the ability to maintain erections, low libido, and penile pain.
CONCLUSIONS: Among men with PD, there is a very high prevalence of emotional and relationship problems. Loss of penile length and inability to have intercourse are strong predictors of these problems and as such make ideal targets for intervention. Medical and surgical therapies may enhance quality of life through their ability to improve sexual function. Further research will characterize the ways in which individual symptoms affect emotional and psychological well-being.

Entities:  

Mesh:

Year:  2008        PMID: 18638001      PMCID: PMC2881678          DOI: 10.1111/j.1743-6109.2008.00949.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  22 in total

1.  Induratio penis plastica: effectivity of low-dose radiotherapy at different clinical stages.

Authors:  H Koren; G Alth; G M Schenk; R H Jindra
Journal:  Urol Res       Date:  1996

2.  Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study.

Authors:  Wolfgang Weidner; Ekkehard W Hauck; Jörg Schnitker
Journal:  Eur Urol       Date:  2005-01-13       Impact factor: 20.096

Review 3.  Peyronie's disease.

Authors:  John Pryor; Emre Akkus; Gary Alter; Gerald Jordan; Thierry Lebret; Laurence Levine; John Mulhall; Sava Perovic; David Ralph; Walter Stackl
Journal:  J Sex Med       Date:  2004-07       Impact factor: 3.802

4.  Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease.

Authors:  G Cavallini; G Biagiotti; A Koverech; G Vitali
Journal:  BJU Int       Date:  2002-06       Impact factor: 5.588

5.  Liposomal recombinant human superoxide dismutase for the treatment of Peyronie's disease: a randomized placebo-controlled double-blind prospective clinical study.

Authors:  Claus R Riedl; Peter Sternig; Günter Gallé; Florian Langmann; Brigitta Vcelar; Karola Vorauer; Andreas Wagner; Hermann Katinger; Heinz Pflüger
Journal:  Eur Urol       Date:  2005-10       Impact factor: 20.096

6.  The prevalence of Peyronie's disease: results of a large survey.

Authors:  U Schwarzer; F Sommer; T Klotz; M Braun; B Reifenrath; U Engelmann
Journal:  BJU Int       Date:  2001-11       Impact factor: 5.588

7.  A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease.

Authors:  Savino M Di Stasi; Antonella Giannantoni; Robert L Stephen; Giovanni Capelli; Arcangelo Giurioli; Emmanuele A Jannini; Giuseppe Vespasiani
Journal:  J Urol       Date:  2004-04       Impact factor: 7.450

Review 8.  Peyronie's disease (CME).

Authors:  Anthony J Bella; Michael A Perelman; William O Brant; Tom F Lue
Journal:  J Sex Med       Date:  2007-11       Impact factor: 3.802

9.  Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening.

Authors:  John P Mulhall; Steven D Creech; Stephen A Boorjian; Sam Ghaly; Edward D Kim; Ayham Moty; Rodney Davis; Wayne Hellstrom
Journal:  J Urol       Date:  2004-06       Impact factor: 7.450

10.  Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis.

Authors:  Sylvie Delanian; Raphael Porcher; Saida Balla-Mekias; Jean-Louis Lefaix
Journal:  J Clin Oncol       Date:  2003-07-01       Impact factor: 44.544

View more
  41 in total

1.  Long-term results of the surgical treatment of Peyronie's disease with plaque incision and grafting.

Authors:  David J Ralph
Journal:  Asian J Androl       Date:  2011-07-25       Impact factor: 3.285

2.  2018 Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature.

Authors:  Anthony J Bella; Jay C Lee; Ethan D Grober; Serge Carrier; Francois Benard; Gerald B Brock
Journal:  Can Urol Assoc J       Date:  2018-02-22       Impact factor: 1.862

3.  Peyronie's Disease: AUA Guideline.

Authors:  Ajay Nehra; Ralph Alterowitz; Daniel J Culkin; Martha M Faraday; Lawrence S Hakim; Joel J Heidelbaugh; Mohit Khera; Erin Kirkby; Kevin T McVary; Martin M Miner; Christian J Nelson; Hossein Sadeghi-Nejad; Allen D Seftel; Alan W Shindel; Arthur L Burnett
Journal:  J Urol       Date:  2015-06-09       Impact factor: 7.450

Review 4.  Experience in the use of collagenase clostridium histolyticum in the management of Peyronie's disease: current data and future prospects.

Authors:  María Alejandra Egui Rojo; Ignacio Moncada Iribarren; Joaquín Carballido Rodriguez; Juan Ignacio Martinez-Salamanca
Journal:  Ther Adv Urol       Date:  2014-10

5.  Geometrical modified nesbit corporoplasty to correct different types of penile curvature: description of the surgical procedure based on geometrical principles and long-term results.

Authors:  P Vicini; S Di Nicola; G Antonini; E De Berardinis; V Gentile; F De Marco
Journal:  Int J Impot Res       Date:  2016-08-11       Impact factor: 2.896

Review 6.  Intralesional collagenase Clostridium histolyticum in the management of Peyronie's disease: current best practice.

Authors:  Daniel J Cwikla; Faysal A Yafi
Journal:  Ther Adv Urol       Date:  2018-02-08

7.  Diagnosis and Treatment of Peyronie Disease With Both Dorsal and Ventral Plaques Using Doppler Ultrasound: NYU Case of the Month, July 2019.

Authors:  Seth D Cohen
Journal:  Rev Urol       Date:  2019

Review 8.  Collagenase Clostridium Histolyticum: A Review in Peyronie's Disease.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2015-08       Impact factor: 9.546

9.  Intratunical injection of human adipose tissue-derived stem cells prevents fibrosis and is associated with improved erectile function in a rat model of Peyronie's disease.

Authors:  Fabio Castiglione; Petter Hedlund; Frank Van der Aa; Trinity J Bivalacqua; Patrizio Rigatti; Hein Van Poppel; Francesco Montorsi; Dirk De Ridder; Maarten Albersen
Journal:  Eur Urol       Date:  2012-09-24       Impact factor: 20.096

Review 10.  Surgery for Peyronie's disease.

Authors:  Laurence A Levine; Stephen M Larsen
Journal:  Asian J Androl       Date:  2012-11-26       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.